Added to YB: 2025-07-01
Pitch date: 2025-06-29
FAE.MC [neutral]
Faes Farma, S.A.
+10.67%
current return
Author Info
Kroker Equity Research is a value investor that uses Discounted Cash Flow (DCF) Model or the Excess Returns Model to value stocks. Sign up for their newsletter.
Company Info
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally.
Market Cap
EUR 1.4B
Pitch Price
EUR 4.43
Price Target
N/A
Dividend
3.51%
EV/EBITDA
11.35
P/E
13.28
EV/Sales
2.51
Sector
Pharmaceuticals
Category
growth
Faes Farma - A Stock Analysis
FAE.MC (overview - more research needed): Spanish pharma w/ 7.8% rev growth to €510M in 2024; doubling revenue/EBITDA by 2030 via acquisitions (Edol €75M, SIFI €270M) targeting ophthalmology. Core business driven by Bilastine/Calcifediol. Trades 15x fwd P/E with 4% div yield. Risks: integration challenges, product concentration, emerging market FX exposure.
Read full article (24 min)